Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

[1]  A. Gottlieb,et al.  Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey , 2023, Dermatologic Therapy.

[2]  S. Feldman,et al.  Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA , 2023, Dermatology and Therapy.

[3]  A. Gottlieb,et al.  Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis , 2023, RMD Open.

[4]  A. Gottlieb,et al.  Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis , 2023, The Journal of Rheumatology.

[5]  A. Ogdie,et al.  Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry , 2022, Drugs - Real World Outcomes.

[6]  D. Vidal,et al.  Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group , 2022, Dermatologic therapy.

[7]  C. Griffiths,et al.  Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis. , 2022, JAMA dermatology.

[8]  M. D. de Wit,et al.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 , 2022, Nature Reviews Rheumatology.

[9]  L. Coates,et al.  Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) , 2021, Annals of the Rheumatic Diseases.

[10]  A. Gottlieb,et al.  Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis , 2021, Arthritis & rheumatology.

[11]  K. Papp,et al.  Consistent safety profile with up to five years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. , 2021, Journal of the American Academy of Dermatology.

[12]  A. Armstrong,et al.  Psoriasis Prevalence in Adults in the United States. , 2021, JAMA dermatology.

[13]  G. Argenziano,et al.  Real-life efficacy of guselkumab in patients with early psoriatic arthritis. , 2021, Rheumatology.

[14]  A. Gottlieb,et al.  Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis , 2021, The Journal of Rheumatology.

[15]  E. Soriano,et al.  Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced , 2021, RMD Open.

[16]  A. Gottlieb,et al.  Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis , 2020, Arthritis & rheumatology.

[17]  J. Primdahl,et al.  EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update , 2020, Annals of the Rheumatic Diseases.

[18]  L. Coates,et al.  Assessment of the many faces of PsA: single and composite measures in PsA clinical trials , 2020, Rheumatology.

[19]  N. Wei,et al.  Psoriatic Arthritis: What is Happening at the Joint? , 2019, Rheumatology and Therapy.

[20]  Jasvinder A. Singh,et al.  2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis , 2018, Arthritis care & research.

[21]  L. Coates,et al.  Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2‐Year Results From a Multicenter, Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled Phase III Study , 2018, Arthritis care & research.

[22]  I. Olivieri,et al.  Physician’s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study , 2018, The Journal of Rheumatology.

[23]  L. Coates,et al.  Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study , 2016, Arthritis care & research.

[24]  L. Coates,et al.  Treating to target in psoriatic arthritis: how to implement in clinical practice , 2015, Annals of the rheumatic diseases.

[25]  J. Smolen,et al.  Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score , 2015, Annals of the rheumatic diseases.

[26]  S. Feldman,et al.  The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials , 2015, The Journal of dermatological treatment.

[27]  J. Pope,et al.  Minimally Important Difference for Patient-reported Outcomes in Psoriatic Arthritis: Health Assessment Questionnaire and Pain, Fatigue, and Global Visual Analog Scales , 2010, The Journal of Rheumatology.

[28]  T. Pincus,et al.  RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): Agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds , 2010, Arthritis care & research.

[29]  L. Coates,et al.  Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment , 2009, Annals of the rheumatic diseases.

[30]  J. Sampalis,et al.  Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index , 2008, Annals of the rheumatic diseases.

[31]  P. Helliwell,et al.  Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. , 2008, Arthritis and rheumatism.

[32]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[33]  H. Holman,et al.  Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.